Dr Reddy’s Laboratories has reported results for the fourth quarter and year ended March 31, 2018.
The company has reported a fall of 20.76% in its net profit at Rs 176.70 crore for the quarter ended March 31, 2018 as compared to Rs 223.00 crore for the same quarter in the previous year. However, total income of the company increased by 6.03% at Rs 2565.40 crore for quarter under review as compared to Rs 2419.60 crore for the quarter ended March 31, 2017.
On consolidated basis, the company has reported a fall of 19.40% in its net profit after taxes and share of profit of associates at Rs 272.10 crore for the quarter ended March 31, 2018 as compared to Rs 337.60 crore for the corresponding quarter in the FY17. Total consolidated income of the company decreased marginally by 0.93% at Rs 3598.80 crore for quarter under review as compared to Rs 3632.40 crore for the same quarter ended previous year.
For the year ended March 31, 2018, the company has posted a fall of 59.04% in its net profit at Rs 566.90 crore as compared to Rs 1384.10 crore for the previous year. Total income of company decreased by 7.25% at Rs 9563.30 crore for year under review as compared to Rs 10311.00 crore for the year ended March 31, 2017.
For the year ended March 31, 2018, on the consolidated basis, the company has posted fall of 26.72% in its net profit after taxes and share of profit of associates at Rs 946.80 crore as compared to Rs 1292.10 crore for the previous year. However, total income of company has increased marginally by 0.48% at Rs 14436.20 crore for year under review as compared to Rs 14367.60 crore for the year ended March 31, 2017.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1504.25 |
Dr. Reddys Lab | 6263.70 |
Cipla | 1406.25 |
Zydus Lifesciences | 948.20 |
Lupin | 1615.85 |
View more.. |